Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro
Yesilbag et al.,
Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV)..,
Virus Research, doi:10.1016/j.virusres.2021.198384 (In Vitro)
In Vitro study showing that ivermectin can inhibit infection of bovine respiratory disease viral agents BCoV, BPIV-3, BVDV, BRSV and BoHV-1 at the concentrations of 2.5 and 5 μM and in a dose-dependent manner.
15 In Vitro studies support the efficacy of ivermectin
[Boschi, Caly, Croci, De Forni, Delandre, Jeffreys, Jitobaom, Jitobaom (B), Li, Liu, Mody, Mountain Valley MD, Segatori, Surnar, Yesilbag].
Yesilbag et al., 10 Mar 2021, peer-reviewed, 3 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: Virus Research 297 (2021) 198384
Contents lists available at ScienceDirect
Virus Research
journal homepage: www.elsevier.com/locate/virusres
Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV,
BPIV-3, BoHV-1, BCoV and BVDV) in vitro
Kadir Yesilbag *, Eda Baldan Toker, Ozer Ates
Department of Virology, Bursa Uludag University, Faculty of Veterinary Medicine, 16059, Bursa, Turkey
A R T I C L E I N F O
A B S T R A C T
Keywords:
Ivermectin
Antiviral efficiency
In vitro testing
Bovine coronavirus
Bovine viral diarrhea virus
Bovine respiratory syncytial virus
Bovine parainfluenza type 3 virus
Bovine herpesvirus type 1
Bovine respiratory disease (BRD) complex is an important viral infection that causes huge economic losses in
cattle herds worldwide. However, there is no directly effective antiviral drug application against respiratory viral
pathogens; generally, the metaphylactic antibacterial drug applications are used for BRD. Ivermectin (IVM) is
currently used as a broad-spectrum anti-parasitic agent both for veterinary and human medicine on some oc
casions. Moreover, since it is identified as an inhibitor for importin α/β-mediated nuclear localization signal
(NLS), IVM is also reported to have antiviral potential against several RNA and DNA viruses. Since therapeutic
use of IVM in COVID-19 cases has recently been postulated, the potential antiviral activity of IVM against bovine
respiratory viruses including BRSV, BPIV-3, BoHV-1, BCoV and BVDV are evaluated in this study. For these
purposes, virus titration assay was used to evaluate titers in viral harvest from infected cells treated with noncytotoxic IVM concentrations (1, 2.5 and 5 μM) and compared to titers from non-treated infected cells. This
study indicated that IVM inhibits the replication of BCoV, BVDV, BRSV, BPIV-3 and BoHV-1 in a dose-dependent
manner in vitro as well as number of extracellular infectious virions. In addition, it was demonstrated that IVM
has no clear effect on the attachment and penetration steps of the replication of the studied viruses. Finally, this
study shows for the first time that IVM can inhibit infection of BRD-related viral agents namely BCoV, BPIV-3,
BVDV, BRSV and BoHV-1 at the concentrations of 2.5 and 5 μM. Consequently, IVM, which is licensed for
antiparasitic indications, also deserves to be evaluated as a broad-spectrum antiviral in BRD cases caused by viral
pathogens.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit